Top Changes At Bayer And Novartis As Vasella Goes, Reinhardt Returns
This article was originally published in The Pink Sheet
It’s all change at two of Europe’s largest pharmaceutical concerns as leading light Daniel Vasella retires at Novartis and Bayer Healthcare’s chairman Jorg Reinhardt moves across to replace him as non-executive chairman.
You may also be interested in...
Novartis says long-time chairman Daniel Vasella has decided to leave the Swiss drug maker and its board has chosen former COO and current Bayer healthcare division head Jorg Reinhardt to replace him.
AstraZeneca's new CEO Pascal Soriot signaled significant change is afoot for the troubled drug maker by eliminating the jobs of R&D President Martin Mackay and Exec VP-Global Commercial Tony Zook.
The radiotherapeutics sector is attracting a new and diverse group of biopharma players hoping to capitalize on the potential advantages offered by newer therapeutic radioisotopes.